BREAST CANCER

Sarah Premji, MD, discusses recent advancements in the breast cancer treatment landscape.

Datopotamab deruxtecan has shown significant survival benefits in patients with metastatic triple-negative breast cancer, marking a potential breakthrough in therapy options.

During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer.

FDA fast tracks ETX-636, a promising treatment for advanced breast cancer with PIK3CA mutations, aiming to improve patient outcomes.

FDA accepts T-DXd for neoadjuvant HER2-positive breast cancer treatment, promising improved outcomes and safety for high-risk patients.

Dr Sarah Premji discusses advancements in breast cancer treatment, emphasizing community trials, personalized therapies, and how to address unmet patient needs.

A groundbreaking trial reveals trastuzumab deruxtecan significantly improves survival in high-risk HER2-positive breast cancer patients post-neoadjuvant therapy.

During a live event, Sara Nunnery, MD, MSCI, and participants discussed different chemotherapy agents that can be used with pembrolizumab in patients with metastatic triple-negative breast cancer.

FDA approves imlunestrant for advanced breast cancer, enhancing treatment options for patients with ESR1 mutations through innovative genomic profiling.

The FDA approves imlunestrant, offering a new oral treatment option for advanced ER-positive breast cancer, enhancing patient outcomes and management.

FDA prioritizes review of T-DXd for first-line HER2-positive breast cancer treatment, showcasing significant survival benefits in recent studies.

The evERA study reveals promising results for giredestrant in treating advanced ER-positive breast cancer, enhancing progression-free survival for patients.

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPION-Breast01 trial. This is the second of 2 parts from this event.

During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ribociclib in N0 and N1 breast cancer.

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover its potential benefits.

Researchers identify IL-6 as a key biomarker predicting resistance to CDK4/6 inhibitors in metastatic breast cancer, highlighting new therapeutic targets.

A groundbreaking study shows trastuzumab pamirtecan significantly improves progression-free survival in HER2-positive breast cancer patients, marking a major oncology advancement.

During a live event, Neil M. Iyengar, MD, discusses how genomic risk scores and menopausal status guide complex adjuvant therapy choices in breast cancer.

Abemaciclib significantly enhances survival rates in high-risk early breast cancer, establishing its role as a standard treatment alongside endocrine therapy.

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPiCS-02 trial.

FDA reviews gedatolisib for advanced breast cancer, showing significant progression-free survival improvements in pivotal VIKTORIA-1 trial.

A pivotal trial evaluates patritumab deruxtecan for advanced HR-positive, HER2-negative breast cancer, offering hope for patients after standard therapies.

A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from unnecessary treatment escalation.

A new study reveals personalized treatment strategies for HER2-negative breast cancer, optimizing antibody-drug conjugate sequencing based on tumor characteristics.

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment.